ANGELA PETERSON: Open Payments
NPI 1851916365 · REXBURG, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$832 in 45 payments from 14 companies in 2025. Trend: 2023 $619 · 2024 $755 · 2025 $832
Food & beverage: $832
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $243 |
| Vanda Pharmaceuticals Inc. | 4 | $103 |
| Novo Nordisk Inc | 6 | $96 |
| Axsome Therapeutics, Inc. | 3 | $71 |
| Lilly USA, LLC | 4 | $60 |
| Phathom Pharmaceuticals, Inc. | 3 | $48 |
| GlaxoSmithKline, LLC. | 2 | $41 |
| Novartis Pharmaceuticals Corporation | 2 | $35 |
| Amgen Inc. | 2 | $30 |
| Antares Pharma, Inc. | 2 | $29 |
Products named: VRAYLAR, FANAPT, Ozempic, QULIPTA, MOUNJARO, Auvelity, VOQUEZNA, UBRELVY.
Industry payments across ID — which companies pay providers there.
